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Background: Ginsenosides have been shown to exert beneﬁcial pharmacological effects on the central
nervous, cardiovascular, and endocrine systems. We sought to determine whether total ginsenosides
(TG) inhibit monocrotaline (MCT)-induced pulmonary hypertension and to elucidate the underlying
mechanism.
Methods: MCT-intoxicated rats were treated with gradient doses of TG, with or without NG-nitro-L-
arginine methyl ester. The levels of molecules involving the regulation of nitric oxide and mitogen-
activated protein kinase pathways were determined.
Results: TG ameliorated MCT-induced pulmonary hypertension in a dose-dependent manner, as assessed
by the right ventricular systolic pressure, the right ventricular hypertrophy index, and pulmonary arterial
remodeling. Furthermore, TG increased the levels of pulmonary nitric oxide, endothelial nitric oxide
synthase, and cyclic guanosine monophosphate. Lastly, TG increased mitogen-activated protein kinase
phosphatase-1 expression and promoted the dephosphorylation of extracellular signal-regulated protein
kinases 1/2, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase 1/2.
Conclusion: TG attenuates MCT-induced pulmonary hypertension, which may involve in part the regu-
lation of nitric oxide and mitogen-activated protein kinase pathways.
Copyright  2015, The Korean Society of Ginseng, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pulmonary hypertension is a progressive disease associated
with increased constriction and remodeling of the pulmonary
vasculature, ultimately leading to right heart failure. However, the
pathological mechanism of pulmonary hypertension at the mo-
lecular level remains unclear. Nitric oxide (NO) is produced from L-
arginine (L-arg) by endothelial NO synthase (eNOS) and causes
smooth muscle relaxation by the activation of soluble guanylate
cyclase, followed by the accumulation of cyclic guanosineanslational Medicine, The First Afﬁl
s Related to Diseases, Ministry of E
. Sun), shufangw@hotmail.com (S.
ork.
ht  2015, The Korean Society of G
d/4.0/).monophosphate (cGMP) [1]. Evidence suggests that impaired NO
production may lead to pulmonary hypertension [2]. Furthermore,
daily treatment with an NO donor attenuates monocrotaline
(MCT)-induced pulmonary hypertension and pulmonary vascular
remodeling [3].
The mitogen-activated protein kinases (MAPKs)dincluding
threemembers p38MAPK, c-Jun NH2-terminal kinase 1/2 (JNK1/2),
and extracellular signal-regulated protein kinase 1/2 (ERK1/2)dare
a family of central signaling molecules that respond to numerous
stimuli by phosphorylating a variety of substrates includingiated Hospital of Xi’an Jiaotong University School of Medicine, Xi’an, Shaanxi, China.
ducation, Xi’an Jiaotong University School of Medicine, Xi’an, Shaanxi 710061, China.
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trating cellular proliferation, differentiation, survival, apoptosis,
and inﬂammation. Recent evidence supports the notion that
MAPKs may be involved in the remodeling of vasculature [4,5].
Ginsenosides are the main active ingredients in ginseng (Panax
ginsengMeyer), a well-known and popular herbal medicine used in
China. To date, at least 30 different ginsenosides have been
extracted from the roots [6], stems, or leaves of P. ginseng [7].
Several cell culture and animal studies show that ginsenosides
confer beneﬁcial effects on the cardiovascular system through
various mechanisms including adjusting blood pressure, modifying
vasomotor function, stimulating NO production, and inﬂuencing
ion channels [8,9]. We have shown previously that total ginseno-
sides (TG) can inhibit vascular smooth muscle cell proliferation,
carotid neointimal hyperplasia, and ventricular hypertrophy both
in vivo and in vitro [10e12]. However, little is known regarding the
effect of TG on pulmonary hypertension. Therefore, we sought to
investigate whether TG alleviates MCT-induced pulmonary hyper-
tension in rats and to explore whether TG affects signaling path-
ways previously implicated in pulmonary hypertension.
2. Materials and methods
2.1. Materials
TG extracted from P. ginseng Meyer leaves and stems was
received from Professor Rui Zhao (Beijing Naturally Occurring
Drugs Research Institute, China) and quantiﬁed in our laboratory as
described previously [13]. Brieﬂy, TGwas reﬂuxedwith 70% ethanol
and then separated by column chromatography with D101 resin
(Xi’an Jiaotong University School of Medicine, China). For quality
control, TG chemical ﬁngerprints were established on a Phenom-
enex ODS column using high-performance liquid chromatography
at 203 nm. Ten ginsenosides (Rg1, Re, Rb1, Rb2, Rc, Rg2, Rb3, Rg3, Rf,
and Rd) were identiﬁed from TG by comparing retention times with
authentic compounds. The ﬁnal product consisted of 21.60% Re,
18.24% Rg2, 15.36% Rb2, 13.65% Rd, 8.4% Rc, 5.26% Rb1, 5.20% Rg1,
4.64% Rb3, 2.15% Rg3, and 1.97%Rf, accounting for 96.47% of the TG,
and other minor ginsenosides.
MCTwas obtained from Sigma Chemical Co. (St. Louis, MO, USA).
L-Arg and NG-nitro-L-arginine methyl ester (L-NAME, an eNOS
inhibitor) were purchased from Alexis Biochemicals Company
(Lausanne, Switzerland). Bicinchoninic acid protein assay kit was
purchased from Merck (Whitehouse Station, NJ, USA). The NO
detection kit was purchased from Nanjing Jiancheng Bioengi-
neering Institute (Nanjing, China), and the cGMP assay kit was
purchased from Amersham (UK). The reverse transcription-
polymerase chain reaction (RT-PCR) kit was purchased from
TaKaRa (Dalian, China). The primer of eNOS was synthesized by
TaKaRa Biological Engineering Company (TaKaRa, Dalian, China).
Antibodies recognizing eNOS, phospho-ERK1/2 (p-ERK1/2),
phospho-p38MAPK (p-p38MAPK), phospho-JNK1/2 (p-JNK1/2),
mitogen-activated protein kinase phosphatase-1 (MKP-1), and
horseradish peroxidase-conjugated secondary antibody were ob-
tained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and
the catalog numbers were sc-650, sc-23759-R, sc-17852-R, sc-6254,
and sc-370, respectively. All other chemicals were of reagent grade.
2.2. Animals and experimental design
All animal procedures were in accordance with the Regulations
of Experimental Animal Administration issued by the State Com-
mittee of Science and Technology of the People’s Republic of China.
The protocol was approved by the Committee on Animal Research
and Ethics of Xi’an Jiaotong University (Xi’an, China).8 to 12-wk-old male SpragueeDawley rats weighing 180e220 g
were purchased from the Fourth Military Medical University, Xi’an,
China. Two animals per cage were housed under constant tem-
perature (25C) and humidity (50%) and maintained on a 12-h
light/dark cycle. Animals were maintained on standard rodent
chow, and food and water were available ad libitum. Prior to the
initiation of the experiment, rats were acclimatized to the envi-
ronmental conditions for 1 wk.
All rats were given a single intraperitoneal injection (i.p.) of MCT
(60 mg/kg) except for the control group (an equal volume of 0.9%
saline). Each group consisted of 8e10 rats. Rats injected with MCT
were randomly divided into seven groups: (1) MCT groupdrats
were administered with vehicle (i.p.); (2e4) TG groupdrats were
administered (i.p.) with TG at 20, 40, and 80 mg/kg/d (TG was
dissolved in 0.9% saline, and the concentration of TGwas 0.4%, 0.8%,
and 1.6% (w/v), respectively); (5) L-arg groupdrats were given L-arg
(200 mg/kg/d, i.p.); (6) TG þ L-N groupdrats were given intra-
gastric (i.g.) administrations of L-NAME at 20 mg/kg/d and i.p.
administration of TG at 40 mg/kg/d; (7) L-a þ L-N groupdrats were
administered with L-NAME (20 mg/kg/d, i.g.) and L-arg (200 mg/kg/
d, i.p.). Control group rats were given i.p. with vehicle. All treat-
ments continued for 18 d. TG doses were chosen according to our
preliminary experimental results and previous reports [10,14].
2.3. Right ventricular systolic pressure and right ventricular
hypertrophy index measurements
Eighteen days afterMCT/saline injections, all surviving rats were
anesthetized with sodium pentobarbital solution (40 mg/kg), and
right ventricular systolic pressure (RVSP) was measured by right
heart catheterization. The right jugular vein was isolated, and a
small polyethylene catheter (PE-50 tube; American Health &
Medical Supply International Corp., Scarsdale, New York, USA) was
inserted through the right jugular vein via a small transverse cut
and then advanced into the right ventricle (RV) under the guidance
of the pressure waveform. The catheters were ﬁlled with heparin-
ized saline (10 U/ml heparin in 0.9% saline). The other end of the
catheter was connected to a biosignal acquisition processor, and
RVSP was directly measured using PowerLab monitoring hardware
and software (AD Instruments, Colorado Springs, CO, USA). Next,
rats were killed by cervical dislocation under anesthesia. The chest
was opened, and the whole lungs and hearts were excised.
The lungs and body were weighed, and the lung weight (LW)/
body weight (BW) was calculated. The left lungs were removed for
histological analysis, and the right lungs were excised and divided
by the upper and lower lobes. The lower lobe of each groupwas used
for NO and cGMP measurement, and the upper lobe was frozen in
liquid nitrogen for real-time PCR and Western blot analysis.
The RV and left ventricle (LV) plus septum (LV þ S) were
weighed, and the weight ratio of RV/(LV þ S) was calculated to
assess the right ventricular hypertrophy index (RVHI).
2.4. Assessment of pulmonary artery remodeling
Left lungs were ﬁxed in 4% paraformaldehyde, parafﬁn-
embedded, and sectioned at 5 mm. Hematoxylin and eosin (HE)
and elastic Van Gieson (EVG) stainings were performed according
to common histopathological procedures. Pulmonary vascular
remodeling was evaluated by determining wall thickness (WT)
according to the method described by Barth et al [15]. External
diameters (EDs) and WTs of at least 15 pulmonary arteries (50e
100 mm in diameter) in each rat in control, MCT, TG 40 mg/kg, L-arg
200 mg/kg, TG þ L-N, and L-a þ L-N groups were assessed under
400 magniﬁcation using a computerized morphometric system
(Qwin; Leica, Wetzlar, Germany) by two pathologists blinded to
Fig. 1. Effects of TG on (A) RVSP, (B) RVHI, and (C) LW/BW in MCT-induced pulmonary
hypertension rats. Eighteen days after treatment with TG, RVSP was measured by right
heart catheterization. RVHI was calculated as the weight ratio of RV/(LV þ S) and used
to describe the degree of right ventricular hypertrophy. LW/BW was calculated as the
weight ratio of LW/BW. Results are represented as mean  SD. a Statistical signiﬁcance
at p < 0.05 TG þ L-N versus TG 40 mg/kg group. b Statistical signiﬁcance at p < 0.05
L-a þ L-N versus L-arg 200 mg/kg group. * Statistical signiﬁcance at p < 0.05 versus
MCT group. ** Statistical signiﬁcance at p < 0.01 versus MCT group. # Statistical
signiﬁcance at p < 0.05 versus control group. BW, body weight; L-a, L-arginine; L-N, NG-
nitro-L-arginine methyl ester; LW, lung weight; MCT, monocrotaline; RVHI, right
ventricular hypertrophy index; RVSP, right ventricular systolic pressure; TG, total
ginsenosides.
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medial wall thickness was calculated as: WT (%) ¼ (2  WT/
ED)  100%.
2.5. NO and cGMP levels measurement
One-half of the lower lobe of each right lung was used for NO
measurement. Lungs were cut into small pieces and then homog-
enized in ice-cold buffer. The homogenate was then centrifuged at
2,000g for 8 min at 4C. The supernatant was transferred to a cold
microcentrifuge tube, and protein concentrations were determined
using a bicinchoninic acid protein assay. NO levels were deter-
mined spectrophotometrically by measuring total nitrate plus ni-
trite (NO3e þ NO2e) with an NO detection kit according to the
manufacturer’s instructions. Brieﬂy, nitrate was enzymatically
converted into nitrite by nitrate reductase, and nitrite was quanti-
ﬁed using Griess reagent at an absorbance of 550 nm. Results were
expressed as micromoles per gram of protein.
The remaining half of the lower lobe of each right lung was used
for cGMP measurement via radioimmunoassays using a cGMP
assay kit according to the manufacturer’s instructions. Each tissue
sample was homogenized in 1 mL 0.1M HCl. The homogenate was
centrifuged at 3,000g for 10 min at 4C, and the supernatant was
evaporated under a stream of N2 gas. The radioactivity of the su-
pernatant was measured to calculate the cGMP level in the sample,
and the amount (pmol) in pulmonary tissues (1 mg) was calculated.
2.6. Gene expression analysis
Total RNA was extracted from lung tissue using TRIzol (MRC
Company, Cincinnati, USA). RT-PCR was performed with an RT-PCR
kit according to the manufacturer’s instructions, and carried out in
an iCycler iQ Real-Time PCR Detection System (Bio-Rad, Hercules,
CA, USA) with SYBR Green PCR Master Mix (ABI Company,
Warrington, UK). The primers were designed with Express Soft-
ware (ABI Co., Foster, CA, USA). The following primers were used:
eNOS (GenBank accession no. NM_021838) forward, 50-GGC ATC
ACC AGG AAG ACT T-30; reverse, 50-CAC ACG CTT CGC CAT CAC-30
(97 bp product); b-actin (GenBank accession no. NM_031144) for-
ward: 50-TGA CAG GAT GCA GAA GGA GA-30, reverse: 50-TAG AGC-
CAC CAA TCC ACA CA-30 (104 bp product). The results (Ct values) of
the target gene were normalized with b-actin of the same sample,
and expressed relative to controls.
2.7. Western blot analysis
Proteins were extracted from the lung tissues. The protein
samples (5e10 mg) were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred on
polyvinylidene diﬂuoride nylon membranes. The membranes were
incubatedwith primaryantibodies to eNOS, p-ERK1/2, p-p38MAPK,
p-JNK1/2, andMKP-1 at 4C overnight, followed by incubationwith
a horseradish peroxidase-conjugated secondary antibody. An
enhanced chemiluminescence system (ECL Plus; GE Healthcare)
was used to detect immunoblots, and bands were visualized and
quantiﬁed with a lumino-analyzer (LAS-1000; Fujiﬁlm, Tokyo,
Japan). The signal intensity was normalized to b-actin expression.
2.8. Statistical analysis
All data were expressed as mean  standard deviation. Statis-
tical comparisons between groups were performed using a one-
way analysis of variance test followed by the Student t test using
SPSS version 13.0 software (SPSS Inc., Chicago, IL, USA). The level of
statistical signiﬁcance was set at p < 0.05.3. Results
3.1. TG attenuates MCT-induced pulmonary hypertension
MCT-induced pulmonary hypertension in rats was validated via
measurement of RVSP, RVHI, and LW/BW. All these parameters
Fig. 2. Effects of TG on pulmonary arterial remodeling in MCT-induced pulmonary hypertension rats. (A) Histological ﬁndings of the pulmonary arterial (arrows, 400). Top, HE
staining; bottom, EVG staining. HE and EVG stainings were performed according to common histopathological procedures. (B) A semiquantitative histological assessment of medial
wall thickness was calculated as: WT (%) ¼ (2 WT/ED)  100%. MCT markedly increased the percent medial wall thickness of the pulmonary arterial, and TG and L-arg attenuated
MCT-induced medial wall thickening. The effects of TG and L-arg were inhibited by L-NAME. Results are represented as mean  SD. * Statistical signiﬁcance at p < 0.05 versus MCT
group. # Statistical signiﬁcance at p < 0.05 versus control group. ED, external diameter; EVG, elastic Van Gieson; HE, hematoxylin and eosin; L-NAME, NG-nitro-L-arginine methyl
ester; MCT, monocrotaline; TG, total ginsenosides; WT, wall thickness.
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Fig. 3. Effects of TG on NO, eNOS, and cGMP in pulmonary tissues in MCT-induced
pulmonary hypertension rats. (A) NO levels were determined spectrophotometrically
by measuring total nitrate plus nitrite (NO3e þ NO2e). NO level in lung tissues
decreased in MCT group compared with control group (p < 0.05). Notably, TG 40 mg/kg
administration caused a signiﬁcant increase in NO production (p < 0.05), whereas
N. Qin et al / TG suppresses effects of MCT 289were signiﬁcantly higher in the MCT group when compared with
the control group. Administration of TG (20, 40, or 80 mg/kg/d)
signiﬁcantly prevented the increases of RVSP, RVHI, and LW/BW in a
dose-dependent manner. L-Arg also reduced RVSP, RVHI, and LW/
BW. The effects of both TG and L-arg were markedly offset by L-
NAME (Fig. 1).
3.2. TG attenuates MCT-induced pulmonary arterial remodeling
Histological analysis revealed that MCT caused a marked medial
hypertrophy in pulmonary arteries, a widening of alveolar septa,
muscularization in the distal arterioles, and marked periarteritis of
vascular arteries. Treatment with TG 40 (mg/kg) or L-arg (200 mg/
kg) signiﬁcantly attenuated the MCT-induced medial wall thick-
ening of pulmonary arteries with a diameter of 50e100 mM. The
effects of TG and L-arg were partly reversed by L-NAME (Fig. 2).
3.3. Effects of TG on NO, cGMP, and eNOS levels
As shown in Fig. 3, the levels of NO, cGMP, and eNOS protein
expressions decreased signiﬁcantly, but the expression level of
eNOSmRNA increased in theMCTgroup. Treatment with TG 40mg/
kg and L-arg 200 mg/kg increased the levels of NO and cGMP
(Figs. 3A and 3E) and elevated the levels of eNOSmRNA and protein
expressions in lung tissues, whereas these effects were partly
blunted by L-NAME (Figs. 3Be3D).
3.4. Effects of TG on p-ERK1/2, p-p38MAPK, p-JNK1/2, and MKP-1
protein expressions
Western blot analysis showed that p-ERK1/2, p-p38MAPK, and
p-JNK1/2 protein expressions in the MCT group exhibited a signif-
icant increase compared with that in the control group, but MKP-1
protein expression showed a slight increase (p > 0.05). TG treat-
ment obviously decreased the protein expressions of p-ERK1/2, p-
p38MAPK, and p-JNK1/2, and increased the MKP-1 protein
expression, whereas these effects of TG were also partly abolished
by L-NAME (Fig. 4).
4. Discussion
Despite the marked progress has been achieved in the past
decade in the treatment of group I pulmonary hypertension [16,17],
current practices provide merely symptom relief. MCT-inducedthese effects of TG were blocked by L-NAME. (B) The expressions of eNOS in lung
tissues were determined by Western blot; lanes 1, 2, 3, 4, and 5 represent control, MCT,
TG 40 mg/kg, L-arg 200 mg/kg, and TG þ L-N, respectively. MCT signiﬁcantly down-
regulated the expressions of eNOS protein, TG 40 mg/kg restored eNOS protein ex-
pressions in MCT-injured lungs, which were blocked by L-NAME. (C) Bands were
quantiﬁed using a lumino-analyzer, and the data of eNOS protein expressions were
expressed as fold increases normalized to b-actin expression. (D) The eNOS mRNA
levels were analyzed using quantitative real-time PCR, and relative expression levels
were calculated by comparison with the internal b-actin control. The eNOS mRNA
expression increased signiﬁcantly in MCT group, and TG 40 mg/kg and L-arg 200 mg/kg
could further enhance the eNOS mRNA expression. (E) The levels of cGMP in lung
tissues were determined using the radioimmunoassays. The cGMP levels in the MCT
group were signiﬁcantly low compared with control group (p < 0.05). TG 40 mg/kg
treatment could increase cGMP level (p < 0.05) in pulmonary tissues, whereas these
effects of TG were blocked by L-NAME. Results are presented as mean  SD. a Statistical
signiﬁcance at p < 0.05 TG þ L-N versus TG 40 mg/kg group. b Statistical signiﬁcance
at p < 0.05 L-a þ L-N versus L-a 200 mg/kg group. * Statistical signiﬁcance at p < 0.05
versus MCT group. ** Statistical signiﬁcance at p < 0.01 versus MCT group. # Statistical
signiﬁcance at p < 0.05 versus control. cGMP, cyclic guanosine monophosphate;
eNOS, endothelial nitric oxide synthase; L-a, L-arginine; L-NAME, NG-nitro-L-arginine
methyl ester; MCT, monocrotaline; PCR, polymerase chain reaction; TG, total
ginsenosides.
J Ginseng Res 2016;40:285e291290pulmonary hypertension is a well-established model, which is very
similar to human pulmonary hypertension [18]. In this study, the
increase of RVSP, RVHI, and LW/BW in theMCTgroup indicated that
the pulmonary hypertension model was successfully established.
We found that administration of TG (20, 40, 80 mg/kg/d)
signiﬁcantly decreased RVSP, RVHI, and LW/BW in MCT-induced
pulmonary hypertension rats. We also found that the WT of small
pulmonary arteries of TG-treated rats was signiﬁcantly decreased
compared with that in the MCT group. Such ameliorated effects of
TG were markedly neutralized by L-NAME. Our results indicate that
TG exerted a protective effect on pulmonary hypertension, which
might occur by reducing pulmonary arterial pressure, improving
pulmonary vascular remodeling, and regulating the NO signal
transduction pathway.
To prove if the protective effect of TG involves NO signal
transduction pathway, we measured the levels of NO, cGMP, and
eNOS in lung tissues. A previous study showed that MCT selectively
damages pulmonary endothelium, reduces NO production and
secretion, and decreases cGMP levels in lung tissues [19]. In our
study, NO production, cGMP levels, and eNOS protein expression
signiﬁcantly decreased in the MCT group, but the level of eNOS
mRNA expression was higher than those of the control group, in
agreement with other studies that showed that levels of eNOS
mRNA increased in MCT-treated rats although eNOS protein levels
decreased [20,21]. This disparity raises the possibility that even
though therewas stimulation of eNOS transcription in this model of
pulmonary hypertension, there were also factors that interfered
with the translation of the eNOS message and/or augmented
degradation of the enzyme. Ginseng extract administration was
previously shown to enhance NO production, improve vessel wall
thickening, alleviate hypertension, and stimulate nongenomic Akt-
mediated eNOS activation in spontaneously hypertensive rats [22].
Similarly, our results also showed that TG administration increased
NO and cGMP production, and upregulated eNOS mRNA and pro-
tein expressions, whereas these effects were blunted by L-NAME.
Taken together, it appears to be possible that TG could suppress
MCT-induced pulmonary hypertension in rats at least partly by
promoting NO and cGMP formation through upregulation of eNOS
protein expression.
IncreasedMAPK activation has been associatedwith remodeling
of pulmonary arteries in MCT-induced pulmonary hypertension
rats [5,23,24]. MKP-1, a dual speciﬁcity phosphatase induced by
growth factors, may be a negative feedback mechanism in the
control of MAPKs activity in vascular smooth muscle cells [25].
Here, we found that the expressions of p-ERK1/2, p-p38MAPK, and
p-JNK1/2 in pulmonary arteries signiﬁcantly increased in the MCT
group. Furthermore, TG treatment could obviously decrease p-ERK,
p-p38MAPK, and p-JNK1/2 expressions and upregulate MKP-1
expression, which might be the cause for downregulation of ERK,
p38MAPK, and JNK phosphorylation. These results strongly sug-
gested that the molecular mechanism for the effect of TG onFig. 4. Effects of TG on p-ERK1/2, p-p38MAPK, p-JNK1/2, and MKP-1 protein expres-
sions in pulmonary tissues in MCT-induced pulmonary hypertension rats. Eighteen
days after treatment with TG, the protein expressions of p-ERK1/2, p-p38MAPK, p-
JNK1/2, and MKP-1 in lungs were determined by Western blot. (A) Lanes 1, 2, 3, and 4
represent control, MCT, TG (40 mg/kg), and TG þ L-N, respectively. Bands were
quantiﬁed using a lumino-analyzer, and the data of (B) p-ERK1/2, (C) p-p38MAPK, (D)
p-JNK1/2, and (E) MKP-1 expressions were expressed as fold increases normalized to
b-actin expression. Results are represented as mean  SD. a Statistical signiﬁcance at
p < 0.05 TG þ L-N versus TG 40 mg/kg group. * Statistical signiﬁcance at p < 0.05
versus MCT group. ** Statistical signiﬁcance at p < 0.01 versus MCT group. # Statistical
signiﬁcance at p < 0.05 versus control group. L-N, NG-nitro-L-arginine methyl ester;
MCT, monocrotaline; MKP-1, mitogen-activated protein kinase phosphatase-1;
p38MAPK, p38 mitogen-activated protein kinase; p-ERK1/2, phospho-ERK1/2; p-
JNK1/2, phospho-JNK1/2; TG, total ginsenosides.
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of the MAPKs signal pathway. In addition, NO has been shown to
attenuate endothelin-1-induced activation of ERK1/2 in vascular
smooth muscle cells in a cGMP-dependent manner [26]. cGMP was
reported to regulate ERK1/2 and p38MAPK among the MAPKs [27].
The present results also conﬁrmed that L-NAME could partly blunt
the inhibitory effect of TG on the MAPKs signal pathway, demon-
strating the existence of the crosstalk between the NO and MAPK
signal pathways in regulation of the development of pulmonary
hypertension.
In conclusion, our study demonstrates that TG treatment can
attenuate pulmonary hypertension when administered early, in
part by the regulation on the NOecGMP and MAPK signal path-
ways. Our results strongly support the notion that TG has a
promising therapeutic potential for pulmonary hypertension.
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